How much cash does Mineralys Therapeutics, Inc. generate?

Mineralys Therapeutics, Inc. (MLYS) generated -$136.4M in operating cash flow over the trailing twelve months.

What is Mineralys Therapeutics, Inc.'s free cash flow?

After $15.0K of capital expenditures, Mineralys Therapeutics, Inc.'s free cash flow was -$142.4M over the trailing twelve months, up 14.4% year over year.

Where does Mineralys Therapeutics, Inc.'s cash flow data come from?

Every line is extracted from Mineralys Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Mineralys Therapeutics, Inc. MLYS Cash Flow Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Net income	-$151.78M+1.9%	-$154.65M+9.8%	-$171.36M+10.2%	-$190.77M-1.2%	-$188.51M-6.0%
Depreciation and amortization	$50K-15.3%	$59K-3.3%	$61K+7.0%	$57K+14.0%	$50K+16.3%
Stock-based compensation	$22.23M+15.0%	$19.32M+12.5%	$17.17M+18.7%	$14.47M+13.1%	$12.79M+12.8%
Change in accounts payable	——	——	——	——	——
Change in other assets	-$4.92M-99.1%	-$2.47M—	——	——	——
Change in accrued investment income	-$71K-143%	$166K+247%	-$113K+10.3%	-$126K+64.7%	-$357K+15.8%
Net cash from operating activities	-$136.4M+4.2%	-$142.42M+16.9%	-$171.37M+11.1%	-$192.69M0.0%	-$192.66M-15.8%
Proceeds from maturities/sales of investments	$692.5M+62.9%	$425M+4.3%	$407.5M+2.9%	$396M-13.2%	$456M-6.7%
Purchases of fixed maturity securities	$1.03B+26.9%	$814.74M+33.5%	$610.19M+65.6%	$368.55M-2.5%	$377.93M+1.2%
Net cash from investing activities	-$341.82M+12.3%	-$389.75M-92.3%	-$202.69M-839%	$27.42M-64.9%	$78.04M-32.1%
Proceeds from issuance of common stock	——	——	——	——	$189.46M+63,692%
Net cash from financing activities	$425.99M-27.9%	$591M+19.5%	$494.39M—	——	——
Net increase (decrease) in cash	——	——	$120.32M+255%	$33.93M—	——
Accretion (Amortization) of Discounts and Premiums, Investments	$13.46M+36.2%	$9.88M+41.0%	$7.01M-4.3%	$7.32M-7.8%	$7.94M-15.6%
Increase (Decrease) in Accrued Interest Receivable, Net	-$71K-143%	$166K+247%	-$113K+10.3%	-$126K+64.7%	-$357K+15.8%
Increase (Decrease) in Prepaid Expense and Other Assets	-$4.92M-99.1%	-$2.47M—	——	——	——
Payments to Acquire Held-to-Maturity Securities	$1.03B+26.9%	$814.74M+33.5%	$610.19M+65.6%	$368.55M-2.5%	$377.93M+1.2%
Payments Of Stock Issuance Costs	$382K-2.3%	$391K+194%	$133K-8.3%	$145K-62.0%	$382K-12.2%
Public offering and shelf offering costs included in accounts payable and accrued liabilities	——	——	——	——	-$32K—
Free cash flow	——	-$142.43M+16.9%	-$171.37M+11.1%	-$192.72M0.0%	-$192.7M-15.8%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does Mineralys Therapeutics, Inc. generate?: Mineralys Therapeutics, Inc. (MLYS) generated -$136.4M in operating cash flow over the trailing twelve months.
What is Mineralys Therapeutics, Inc.'s free cash flow?: After $15.0K of capital expenditures, Mineralys Therapeutics, Inc.'s free cash flow was -$142.4M over the trailing twelve months, up 14.4% year over year.
Where does Mineralys Therapeutics, Inc.'s cash flow data come from?: Every line is extracted from Mineralys Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.